BMC Cancer 2005, 5:77 http://www.biomedcentral.com/1471-2407/5/77 dom chromosomal aberrations in early preinvasive cervical lessions. Cancer Genet Cytogenet 2001, 129:47-51. 13. Umayahara K, Numa F, Suehiro Y, Sakata A, Nawata S, Ogata H, Sum- inami Y, Sakamoto M, Sasaki K, Kato H: Comparative Genomic Hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chrom Cancer 2002, 33:98-102. 14. Harris CP, Lu XY, Narayan G, Singh B, Murty VV, Rao PH: Compre- hensive molecular cytogenetic characterization of cervical cancer cell lines. Genes Chrom Cancer 2003, 36:233-241. 15. Narayan G, Pulido HA, Koul S, Lu XY, Harris CP, Yeh YA, Vargas H, Posso H, Terry MB, Gissmann L, Schneider A, Mansukhani M, et al.: Genetic analysis identifies putative tumor supressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression. Oncogene 2003, 22:3489-3499. 16. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, Narayan G, Schneider A, Terry MB, Murty VV: Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the fre- quent genetic changes in cervical carcinoma. BMC Cancer 2004, 4:5. 17. Solinas-Toldo S, Dürst M, Lichter P: Specific chromosomal imbal- ances in human papillomavirus transfected cells during pro- gression toward immortality. Proc Natl Acad Sci USA 1997, 94:3854-3859. 18. Hidalgo A, Schewe C, Petersen S, Salcedo M, Gariglio P, Schlüns K, Dietel M, Petersen I: Human papilloma virus status and chro- mosomal imbalances in primary cervical carcinomas and tumor cell lines. Eur J Cancer 2000, 36:542-548. 19. Hidalgo A, Monroy A, Arana R, Taja L, Vázquez G, Salcedo M: Chro- mosomal imbalances in four new uterine cervix carcinoma derived cell lines. BMC Cancer 2003, 3(1):8. 20. Lichter P, Joos S, Bentz M, Lampel S: Comparative genomic hybridization: uses and limitations. Semin Hematol 2000, 37:348-357. 21. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P: Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chrom Cancer 1997, 20:399-407. 22. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, et al.: High reso- lution analysis of DNA copy number variation using compar- ative genomic hybridization to microarrays. Nature Genet 1998, 20:207-211. 23. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature Genet 1999, 23:41-46. 24. Caceres-Cortes JR, Alvarado-Moreno JA, Waga K, Rangel-Corona R, Monroy-Garcia A, Rocha-Zavaleta L, Urdiales-Ramos J, Weiss-Steider B, Haman A, Hugo P, Brousseau R, Hoang T: Implication of tyro- sine kinase receptor and steel factor in cell density-depend- ent growth in cervical cancer and leukemias. Cancer Res 2001, 61:6281-6289. 25. Baudis M, Cleary ML: Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics 2001, 17:1228-1229. 26. Giarnieri E, Mancini R, Pisani T, Alderisio M, Vecchione A: Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Can- cer Res 2000, 6:3600-3606. 27. Kwasniewska A, Gozdzicka-Jozefiak A, Postawski K, Miturski R: Eval- uation of DNA mismatch repair system in cervical dysplasias and invasive carcinomas related to HPV infection. Eur J Gynae- col Oncol 2002, 23:231-235. 28. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F: p63 is essential for regenerative proliferation in limb, craniofacial and epi- thelial development. Nature 1999, 398:714-718. 29. Quade BJ, Yang A, Wang Y, Sun D, Park J, Sheets EE, Cviko A, Feder- schneider JM, Peters R, McKeon FD, Crum CP: Expression of the p53 homologue p63 in early cervical neoplasia. Gynecol Oncol 2001, 80:24-29. 30. Wang T, Chen B, Yang Y, Chen H, Wang Y, Cviko A, Quade B, Sun D, Yang A, Mckeon F, Crum C: Histologic and immunopheno- typic classification of cervical carcinomas by expression of the p53 homologue p63: A study of 250 cases. Hum Pathol 2001, 32:479-486. 31. Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ: P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervi- cal squamous cell carcinoma. Gynecol Oncol 2003, 91:346-353. 32. Chen H, Toyooka S, Gazdar AF, Hsieh JT: Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate can- cer cell lines. J Biol Chem 2003, 278:3121-3130. 33. Yang DH, Smith ER, Cohen C, Wu H, Patriotis C, Godwin AK, Ham- ilton TC, Xu XX: Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer 2002, 94:2380-2392. 34. Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX: Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene 2000, 19:4847-4854. 35. Huang LW, Chao SL, Chen TJ: Reduced Fhit expression in cervi- cal carcinoma: correlation with tumor progression and poor prognosis. Gynecol Oncol 2003, 90:331-337. 36. Butler D, Collins C, Mabruk M, Leader MB, Kay EW: Loss of Fhit expression as a potential marker of malignant progression in preinvasive squamous cervical cancer. Gynecol Oncol 2002, 86:144-149. 37. Takizawa S, Nakagawa S, Nakagawa K, Yasugi T, Fujii T, Kugu K, Yano T, Yoshikawa H, Taketani Y: Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer. Br J Cancer 2003, 88:1213-1216. 38. Thorland EC, Myers SL, Gostout BS, Smith DI: Common fragile sites are preferential targets for HPV16 integrations in cer- vical tumors. Oncogene 2003, 22:1225-1237. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/5/77/prepub Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 7 of 7 (page number not for citation purposes)